Analystreport

Merrimack Pharmaceuticals Inc (NASDAQ: MACK) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.

Merrimack Pharmaceuticals, Inc.  (MACK) 
Last merrimack pharmaceuticals, inc. earnings: 3/6 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.merrimack.com/investor-relations